Orexigen appoints Dr Dennis Kim
This article was originally published in Scrip
Orexigen Therapeutics (US) has appointed Dr Dennis Kim senior vice-president and head of obesity and metabolic disorders. Dr Kim was previously chief medical officer and vice-president of medical affairs at EnteroMedics. Orexigen has a potential obesity product Contrave (sustained-release naltrexone and bupropion) in Phase III clinical trials.
You may also be interested in...
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.